Leukotriene B4 inhibitors: US2009054466; US2009227603 and US2009253684.
Three US applications describing a narrow, closely related series of antagonists of the action of leukotriene B(4) on the BLT1 and BLT2 receptors are described. The generic structure claimed is a lipophilic linked diphenyl core containing two acid groups appended to the central phenyl ring. The terminal phenyl moiety contains disubstitution at the 3'- and 5'-positions. These three applications differ in the nature of the substituent on the terminal phenyl group as well as the linking moiety between the two phenyl rings. These compounds are claimed to have utility in inflammatory diseases such as severe asthma and chronic obstructive pulmonary disease.
Hutchinson
John H
JH
Amira Pharmaceuticals, Inc., 9535 Waples Street, Suite 100, San Diego, CA 92121, USA. john.hutchinson@amirapharm.com
D000818:Animals; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000503:physiopathology; D020024:Leukotriene Antagonists / Q000737:chemistry / Q000494:pharmacology*; D007975:Leukotriene B4 / Q000037:antagonists & inhibitors*; D010330:Patents as Topic; D018102:Receptors, Leukotriene B4 / Q000037:antagonists & inhibitors*
C513240:LTB4R protein, human; C485878:LTB4R2 protein, human; D020024:Leukotriene Antagonists; D018102:Receptors, Leukotriene B4; D007975:Leukotriene B4